Ideaya wraps $50M IPO to fuel clinical drive on synthetic lethality
Ideaya Biosciences has followed several other downsized IPOs onto the Nasdaq, beginning a new public life with a $50 million raise and the ticker symbol $IDYA.
Led by CEO Yujiro Hata, an experienced biotech exec who built the South San Francisco company from scratch while an entrepreneur-in-residence at 5AM, Ideaya is all about targeted cancer therapies and synthetic lethality — the strategy of targeting two genes simultaneously for a more potent effect. It’s starting out with an early-stage drug picked up for a song from Novartis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.